Correction: Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells


The author affiliations and funding statement has been updated.

The following affiliations have been added to Juan Roberto Rodriguez-Madoz, Jesús San Miguel, Felipe Prosper and Juan Jose Lasarte:

Centro de Investigacion Biomedica en Red de Cancer (CIBERONC)

Cancer Center Universidad de Navarra (CCUN)

The below information has been added to the funding statement:

ISCiii Retic Tercel RD16/011/0005 funded by ISCiii+Fondos FEDER, Red de Terapias Avanzadas TERAV (RD21/0017/0009) funded by ISCiii+Unión Europea – NextGenerationEU Plan de Recuperación Transformación y Resiliencia

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e004479corr1. doi:10.1136/jitc-2021-004479corr1